Clinical Trials on B-Lymphoid Malignancies

Total 13071 results

Shanghai Escugen Biotechnology Co., Ltd

Recruiting

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

China
Shanghai Escugen Biotechnology Co., Ltd
Escugen (Australia) Biotechnology Pty Ltd

Not yet recruiting

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies
AbbVie
Genentech, Inc.

Active, not recruiting

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Non-Hodgkin's Lymphoma | Hematological Malignancies | Chronic Lymphoid Leukemia | CD20-Positive Lymphoid Malignancies

United States, Australia
Baptist Health South Florida

Withdrawn

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Non-Hodgkin Lymphoma | Hematologic Malignancy | B-Cell Lymphoid Malignancies

United States
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Peripheral T-cell Lymphoma | Lymphoid Malignancies | Chronic Lymphoid Leukemia

United States, Canada
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
Anand B. Karnad

Completed

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Advanced B-cell Lymphoid Malignancies

United States
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
Gilead Sciences

Terminated

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's Lymphoma

United States, Canada
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Leukemia

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
Innovative Cellular Therapeutics Co., Ltd.

Unknown

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Lymphoma, B-Cell | Leukemia, B-Cell

China
M.D. Anderson Cancer Center

Completed

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | B-Lymphoid Malignancies | Non-hodgkin Lymphoma

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Xuzhou Medical University

Recruiting

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Unknown

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | B-Cell Non-Hodgkin Lymphomas(NHL)

China
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Sunesis Pharmaceuticals

Completed

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | B-lymphoid Malignancies

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Hangzhou Zenshine Pharmaceuticals Co., Ltd.

Terminated

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Non-hodgkin Lymphoma

United States
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China
Agenus Inc.

Completed

Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma

B-Cell Lymphoma | Malignancies

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide (CLL1818)

Chronic Lymphoid Leukemia | Large-B-cell Diffuse Lymphoma

Italy
University of Milano Bicocca

Recruiting

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

Mantle-cell Lymphoma | B Cell Chronic Lymphocytic Leukemia

Italy
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Amgen

Completed

AMG 319 Lymphoid Malignancy FIH

Lymphoma | Leukemia | Cancer | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Hematologic Malignancies | Diffuse Large Cell Lymphoma | Oncology | Tumors | T Cell Lymphoma | Oncology Patients | Hematology | Low Grade Lymphoma

United States
AstraZeneca

Active, not recruiting

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

China
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

Lymphoma, B-Cell | Follicular Lymphoma | Large B-cell Lymphoma

China
TransThera Sciences (Nanjing), Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

B-Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Incyte Corporation

Completed

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

B-Cell Malignancies

United States
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Shanghai Tongji Hospital, Tongji University School...

Recruiting

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Incyte Corporation

Active, not recruiting

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

B-cell Malignancies

United States
Gilead Sciences

Active, not recruiting

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

B-cell Malignancies

United States, United Kingdom, France
BeiGene

Completed

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

B-cell Malignancies

Australia
Shanghai YingLi Pharmaceutical Co. Ltd.

Completed

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China

Clinical Trials on B-Lymphoid Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations